Skip to main content
Skip to main content

AAP Gateway

Advanced Search »

User menu

  • Login
  • Current Policy
  • Topic/Program Collections
  • Submit Manuscript
  • Alerts
  • Subscribe
  • aap.org

Menu

  • AAP Grand Rounds
  • AAP News
  • Hospital Pediatrics
  • NeoReviews
  • Pediatrics
  • Pediatrics in Review
  • Current AAP Policy
  • Journal CME
  • AAP Career Center
  • Pediatric Collections
  • AAP Journals Catalog

Sections

    • Login
    • Current Policy
    • Topic/Program Collections
    • Submit Manuscript
    • Alerts
    • Subscribe
    • aap.org

    Sign up for Insight Alerts highlighting editor-chosen studies with the greatest impact on clinical care.

    New! Video Abstracts -- brief videos summarizing key findings of new articles

    Know what's next when you read AAP Journals, view the new 2018 Catalog.
    Trainees,
    enter the SOPT Essay Contest for a chance to be published in Pediatrics!

    Advertising Disclaimer »

    Tools and Links

    Pediatrics
    November 2009, VOLUME 124 / ISSUE Supplement 2
    From the American Academy of Pediatrics
    MEDICAL THERAPIES

    Daily Versus As-Needed Inhaled Corticosteroid for Mild Persistent Asthma (The Helsinki Early Intervention Childhood Asthma Study)

    John M. Kelso
    • Article
    • Info & Metrics
    • Comments
    Loading
    Download PDF

    Turpeinen M, Nikander K, Pelkonen AS, et al. Arch Dis Child. 2008;93(8):654–659

    PURPOSE OF THE STUDY. To compare the effect on mild persistent asthma of inhaled budesonide given daily or as needed.

    METHODS. A total of 176 children 5 to 10 years of age with newly diagnosed asthma were randomly assigned to 3 treatment groups, (1) continuous budesonide dry powder inhaler, given at 400 mg twice daily for 1 month, 200 mg twice daily for months 2 to 6, and 100 mg twice daily for months 7 to 18; (2) budesonide treatment identical to group 1 for months 1 to 6 and then placebo for months 7 to 18; or (3) cromolyn metered dose inhaler at 10 mg 3 times daily for months 1 to 18 (control group). All patients were given rescue medication (terbutaline, 0.25 mg per dose) as needed. For all groups, during exacerbations of asthma, study medication was replaced by budesonide at 400 mg twice daily for 2 weeks. Outcome measures were lung function, number of exacerbations, number of asthma-free days, and growth.

    RESULTS. Compared with cromolyn (group 3), the initial regular budesonide treatment (groups 1 and 2) resulted in significantly improved lung function (increase in forced expiratory volume in 1 second of 9.6% vs 5.9%), fewer exacerbations per patient (0.32 vs 1.24 exacerbations), more asthma-free days (increase of 20.1% vs 4.1%), and a small but significant decrease in growth velocity. After 18 months, the lung function improvements did not differ between the groups. During months 7 to 18, patients receiving continuous budesonide treatment had fewer exacerbations per patient (0.97 exacerbations, compared with 1.69 exacerbations in group 2 and 1.58 exacerbations in group 3). Three patients in group 1 and 9 patients in group 2 were withdrawn because of asthma deterioration after 6 months of treatment. The number of asthma-free days did not differ between groups 1 and 2 but remained better than in group 3. Growth velocity was normalized in groups 1 and 2.

    CONCLUSIONS. Regular use of budesonide afforded better asthma control but had a more systemic effect than did as-needed use of budesonide.

    REVIEWER COMMENTS. It is not a surprise that the inhaled corticosteroids achieved better asthma control than did cromolyn and are the preferred medications. The question addressed by this study is whether inhaled corticosteroids can be used as needed versus continuously. Although these 2 approaches did not differ in lung function or number of asthma-free days, the continuous-treatment group had significantly fewer exacerbations. An accompanying editorial (Pedersen S. Arch Dis Child. 2008;93[8]:644–645) asks, “Do the benefits of daily inhaled steroid treatment of mild asthma outweigh the risks?” and answers in the affirmative, noting that regular use is safe (6 of 7 studies found no long-term effects on growth), as well as more effective and less expensive than any other treatment.

    • Copyright © 2009 by the American Academy of Pediatrics
    View Abstract
    PreviousNext

     

    Advertising Disclaimer »

    View this article with LENS
    PreviousNext
    Email

    Thank you for your interest in spreading the word on Pediatrics.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Daily Versus As-Needed Inhaled Corticosteroid for Mild Persistent Asthma (The Helsinki Early Intervention Childhood Asthma Study)
    (Your Name) has sent you a message from Pediatrics
    (Your Name) thought you would like to see the Pediatrics web site.

    Alerts
    Sign In to Email Alerts with your Email Address
    Citation Tools
    Daily Versus As-Needed Inhaled Corticosteroid for Mild Persistent Asthma (The Helsinki Early Intervention Childhood Asthma Study)
    John M. Kelso
    Pediatrics Nov 2009, 124 (Supplement 2) S148-S149; DOI: 10.1542/peds.2009-1870QQQ

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Daily Versus As-Needed Inhaled Corticosteroid for Mild Persistent Asthma (The Helsinki Early Intervention Childhood Asthma Study)
    John M. Kelso
    Pediatrics Nov 2009, 124 (Supplement 2) S148-S149; DOI: 10.1542/peds.2009-1870QQQ
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Print
    PDF
    Insight Alerts
    • Table of Contents
    • Current Policy
    • Early Release
    • Current Issue
    • Past Issues
    • Editorial Board
    • Editorial Policies
    • Overview
    • Open Access
    • Pediatric Collections
    • Video Abstracts
    • Author Guidelines
    • Reviewer Guidelines
    • Submit My Manuscript

    Subjects

    • Allergy/Immunology
      • Asthma
      • Allergy/Immunology
    Back to top

                

    Copyright (c) 2018 by American Academy of Pediatrics

    International Access »           

    Terms of Use
    Privacy Statement
    FAQ

    AAP Pediatrics